AbbVie (ABBV)
Technical, fundamental, and sentiment analysis with recent related videos.
ABBV rates Bullish overall. The fundamental read is neutral: the company passes 7 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.75); revenue is growing about 2.0% per year; net income is declining about 24.0% per year. The technical picture is bullish: price is 23.2% above the 200-day moving average; 8.0% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +2.0%. Net income 3-year avg -24.0%.
Price vs 20DMA +4.2%. RSI 67.08. Bollinger state: Inside Bands.
Composite score 72/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
AbbVie’s badges split three ways: Fundamental is Neutral because revenue averaged 2.0 percent per year while net income fell an average of 24.0 percent per year, so profitability drags the score. Technical is Bullish: price sits +4.2 percent versus its 20-day moving average (the recent short-term average), the Relative Strength Index (RSI, a momentum reading) is 67.1, and the stock remains inside its Bollinger Bands (a volatility channel). Sentiment is Bullish, composite 72, and the two Bullish signals outweigh the Neutral fundamental, producing an Overall Bullish read.
Recent news: Coverage in the Global Database of Events, Language, and Tone (GDELT) and Internet Archive TV coverage spotlight billionaire Ken Griffin buying AbbVie shares and the FDA approving a subcutaneous induction regimen for SKYRIZI in moderate-to-severe Crohn’s disease, which expand commercial opportunity. Journalists also flagged an Oct. 30 Q3 report, options implying about a 5 percent expected move, and lingering concern after last quarter’s guidance cut. Recent videos focused on broader biotech names rather than AbbVie specifically.